Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar(University of Washington), Jordan Gauthier(Seattle Cancer Care Alliance), David G. Maloney(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Xinyi Fan(Fred Hutch Cancer Center), Mazyar Shadman(University of Washington), Christina Poh(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Jenna Voutsinas(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Ryan D. Cassaday(University of Washington), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jennifer J. Huang(Stanford Medicine), Erik L. Kimble(University of Washington)
Blood
November 2, 2023
10.1182/blood-2023-180128
Cited by 1

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603